HIV-1 integrase inhibitors: A review of their chemical development

Antiviral Chemistry and Chemotherapy

Volumn 22, Issue 3, 2012, Pages 95-105

  Ingale, Kundan B ^a   Bhatia, Manish S ^a  

^a BHARATI VIDYAPEETH COLLEGE OF PHARMACY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 2,6 BISBENZYLIDENECYCLOHEXANE 1 ONE DERIVATIVE; 4 [1 (4 FLUOROBENZYL) 2 PYRROLYL] 2,4 DIOXOBUTYRIC ACID; 6 ARYL 2,4 DIOXO 5 HEXANOIC ACID DERIVATIVE; 8 HYDROXYQUINOLINE 7 CARBOXYLIC ACID DERIVATIVE; ALPHA GAMMA DIKETO ACID DERIVATIVE; BUTANOIC ACID DERIVATIVE; CICHORIC ACID; COMPLEMENTARY DNA; ELVITEGRAVIR; GLOBOIDNAN A; INTEGRASE; INTEGRASE INHIBITOR; L 708906; NAPHTHYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINOLONE DERIVATIVE; RALTEGRAVIR; RDS 1699; S GSK 364735; UNCLASSIFIED DRUG; VIRUS DNA;

AMINO TERMINAL SEQUENCE; BIOASSAY; CARBOXY TERMINAL SEQUENCE; CHEMICAL ANALYSIS; CLINICAL TRIAL (TOPIC); CRYSTAL STRUCTURE; DNA REPAIR; DNA TRANSFER; DRUG MECHANISM; DRUG PURIFICATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME STRUCTURE; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; LONG TERMINAL REPEAT; NONHUMAN; PHARMACOPHORE; PHASE 2 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; THERAPY RESISTANCE; VIRUS DNA CELL DNA INTERACTION; VIRUS GENE; VIRUS REPLICATION; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECT; METABOLISM; VIROLOGY;

DRUG DISCOVERY; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HUMANS;

EID: 84861546863     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1740     Document Type: Review

References (65)

1. Engelman A, Craigie R. Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. J Virol 1992; 66:6361-6369.
2. Engelman A, Bushman FD, Craigie R. Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex. EMBO J 1993; 12:3269-3275.
3. van Gent DC, Vink C, Groeneger AA, Plasterk RH. Complementation between HIV integrase proteins mutated in different domains. EMBO J 1993; 12:3261-3267.
4. Sloan RD, Wainberg MA. The role of unintegrated DNA in HIV infection. Retrovirology 2011; 8:52.
5. Dyda F, Hickman AB, Jenkins TM, Engelman A, Craigie R, Davies DR. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 1994; 266:1981-1986.
6. Goldgur Y, Dyda F, Hickman AB, Jenkins TM, Craigie R, Davies DR. Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc Natl Acad Sci U S A 1998; 95:9150-9154.
7. Chen JC, Krucinski J, Miercke LJ, et al. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc Natl Acad Sci U S A 2000; 97:8233-8238.
8. Greenwald J, Le V, Butler SL, Bushman FD, Choe S. The mobility of an HIV-1 integrase active site loop is correlated with catalytic activity. Biochemistry 1999; 38:8892-8898.
9. Maignan S, Guilloteau J P, Zhou-Liu Q, Clement-Mella C, Mikol V. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J Mol Biol 1998; 282:359-368.
10. van Gent DC, Groeneger AA, Plasterk RH. Mutational analysis of the integrase protein of human immunodeficiency virus type 2. Proc Natl Acad Sci U S A 1992; 89:9598-9602.
11. Freemont PS, Friedman JM, Beese LS, Sanderson MR, Haniford SD. Minireview: HIV integrase. Proc Natl Acad Sci U S A 1988; 85:8924-8928.
12. Zheng R, Jenkins TM, Craigie R. Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity. Proc Natl Acad Sci U S A 1996; 93:13659-13664.
13. Lodi PJ, Ernst JA, Kuszewski J, et al. Solution structure of the DNA binding domain of HIV-1 integrase. Biochemistry 1995; 34:9826-9833.
14. Eijkelenboom AP, Lutzke RA, Boelens R, Plasterk RH, Kaptein R, Hard K. The DNA-binding domain of HIV-1 integrase has an SH3-like fold. Nat Struct Biol 1995; 2:807-810.
15. Katzman M, Sudol M. Mapping domains of retroviral integrase responsible for viral DNA specificity and target site selection by analysis of chimeras between human immunodefciency virus type 1 and visna virus integrases. J Virol 1995; 69:5687-5696.
16. Shibagaki Y, Chow SA. Central core domain of retroviral integrase is responsible for target site selection. J Biol Chem 1997; 272:8361-8369.
17. Esposito D, Craigie R. Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction. EMBO J 1998; 17:5832-5843.
18. Sakurai Y, Komatsu K, Agematsu K, Matsuoka M. DNA double strand break repair enzymes function at multiple steps in retroviral infection. Retrovirology 2009; 6:114.
19. Goldgur Y, Craigie R, Cohen GH, Fugiwara T, Yoshinaga T, Fujishita T. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc Natl Acad Sci U S A 1999; 96:13040-13043.
20. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287:646-650.
21. Li X, Vince R. Conformationally restrained carbazolone-containing a,B-diketo acids as inhibitors of HIV integrase. Bioorg Med Chem 2006; 14:2942-2955.
22. Di Santo R, Costi R, Artico M, Tramontano E, Colla PL, Pani A. HIV-1 integrase inhibitors that block HIV-1 replication in infected cells. Planning synthetic derivatives from natural products. Pure Appl Chem 2003; 75:195-206.
23. Wai JS, Egberston MS, Payne LS, et al. 4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. J Med Chem 2000; 43:4923-4926.
24. Sechi M, Sannia L, Carta F, et al. Design of novel bioisosteres of beta-diketo acid inhibitors of HIV-1 integrase. Antivir Chem Chemother 2005; 16:41-61.
25. Patil S, Kamath S, Sanchez T, Neamati N, Schinazic RF, Buolamwinia JK. Synthesis and biological evaluation of novel 5(H)-phenanthridin-6-ones, 5(H)-phenanthridin-6-one diketo acid, and polycyclic aromatic diketo acid analogs as new HIV-1 integrase inhibitors. Bioorg Med Chem 2007; 15:1212-1228.
26. Svarovskaia ES, Barr R, Zhang X, et al. Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions. J Virol 2004; 78:3210-3222.
27. Cushman M, Sherman P. Inhibition of HIV-1 integration protein by aurintricarboxylic acid monomers, monomer analogs, and polymer fractions. Biochem Biophys Res Commun 1992; 185:85-90.
28. LaFemina RL, Graham PL, Legrow K, et al. Inhibition of human immunodeficiency virus integrase by bis-catechols. Antimicrob Agents Chemother 1995; 39:320-324.
29. Mazumder A, Wang S, Neamati N, et al. Antiretroviral agents as inhibitors of both human immunodefciency virus type 1 integrase and protease. J Med Chem 1996; 39:2472-2481.
30. Fesen MR, Pommier Y, Leteurtre F, Hirogouchi S, Yung J, Kohn KW. Inhibition of HIV-1 integrase by favones, caffeic acid phenethyl ester (CAPE) and related compounds. Biochem Pharmacol 1994; 48:595-608.
31. Mazumder A, Raghavan K, Weinstein K, Kohn KW, Pommier Y. Inhibition of human immunodeficiency virus type-1 integrase by curcumin. Biochem Pharmacol 1995; 49:1165-1170.
32. Mazumder A, Neamati N, Sunder S, et al. Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action. J Med Chem 1997; 40:3057-3063.
33. Mazumder A, Gazit A, Levitzki A, et al. Effects of tyrphostins, protein kinase inhibitors, on human immunodeficiency virus type 1 integrase. Biochemistry 1995; 34:15111-15122.
34. Eich E, Pertz H, Kaloga M, et al. (-)-Arctigenin as a lead structure for inhibitors of human immunodeficiency virus type-1 integrase. J Med Chem 1996; 39:86-95.
35. Zhao H, Neamati N, Hong H, et al. Coumarin-based inhibitors of HIV integrase. J Med Chem 1997; 40:242-249.
36. Cushman M, Golebiewsky WM, Pommier Y, et al. Cosalane analogs with enhanced potencies as inhibitors of HIV-1 protease and integrase. J Med Chem 1995; 38:443-452.
37. Neamati N, Hong H, Mazumder A, et al. Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. J Med Chem 1997; 40:942-951.
38. Reddy MVR, Rao MR, Rhodes D, et al. Lamellarin α 20-sulfate, an inhibitor of HIV-1 integrase active against HIV-1 virus in cell culture. J Med Chem 1999; 42:1901-1907.
39. Ovenden SP, Simon PB, Yu J, et al. Globoidnan A: a lignan from Eucalyptus globoidea inhibits HIV integrase. Phytochemistry 2004; 65:3255-3259.
40. Costi R, Di Santo R, Artico M, et al. 2,6-Bis(3,4,5-trihydroxybenzylydene) derivatives of cyclohexanone: novel potent HIV-1 integrase inhibitors that prevent HIV-1 multiplication in cell-based assays. Bioorg Med Chem 2004; 12:199-215.
41. Robinson WE, Reinecke MG, Abdel MS, Jia Q, Chow SA. Inhibitors of HIV-1 replication that inhibit HIV integrase. Proc Natl Acad Sci U S A 1996; 93:6326-6331.
42. Neamati N, Hong HX, Sunder S, Milne GWA, Pommier Y. Potent inhibitors of human immunodefciency virus type 1 integrase: identifcation of a novel four-point pharmacophore and tetracyclines as novel inhibitors. Mol Pharmacol 1997; 52:1041-1055.
43. Bénard C, Zouhiri F, Normand-Bayle M, et al. Linker-modifed quinoline derivatives targeting HIV-1 integrase: synthesis and biological activity. Bioorg Med Chem Lett 2004; 14:2473-2476.
44. Mekouar K, Mouscadet JF, Desmaele D, et al. Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells. J Med Chem 1998; 41:2846-2857.
45. Sato M, Motomura T, Aramaki H, et al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem 2006; 49:1506-1508.
46. Cecchetti V, Parolin C, Moro S, et al. 6-Aminoquinolones as new potential anti-HIV agents. J Med Chem 2000; 43:3799-3802.
47. Mekouar K, D'Angelo J, Desmaele D, Mouscadet JF, Subra F, Auclair C, inventors; CNRS assignee. Quinoline derivatives having in particular antiviral properties, preparation and biological application thereof. WO9845269A1. 1998 October 15.
48. Zouhiri F, Mouscadet JF, Mekouar K, et al. Structure-activity relationships and binding mode of styrylquinolines as potent inhibitors of HIV-1 integrase and replication of HIV-1 in cell culture. J Med Chem 2000; 43:1533-1540.
49. Bonnenfant S, Thomas CM, Vita C, et al. Styrylquinolines, integrase inhibitors acting prior to integration: a new mechanism of action for anti-integrase agents. J Virol 2004; 78:5728-5736.
50. Satoh M, Kawakami H, Itoh Y, et al. inventors; Japan Tobacco Inc., assignee. 4-oxoquinoline compound and use thereof as pharmaceutical agent. WO04046115A1. 2004 June 3.
51. Zhuang L, Wai JS, Embrey MW, et al. Design and synthesis of 8-hydroxy- [1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. J Med Chem 2003; 46:453-456.
52. Guare J P, Pai JS, Gomez RP, et al. A series of 5-aminosubstituted 4-fuorobenzyl-8-hydroxy- [1,6] naphthyridine-7-carboxamide HIV-1 integrase inhibitors. Bioorg Med Chem Lett 2006; 16:2900-2904.
53. Pannecouque C, Pluymers W, Van Maele B, et al. New class of HIV integrase inhibitors that block viral replication in cell culture. Curr Biol 2002; 12:1169-1177.
54. Fikkert V, Maele BV, Vercammen J, et al. Development of resistance against diketo derivatives of human immunodefciency virus type 1 by progressive cumulation of integrase mutations. J Virol 2003; 77:11459-11470.
55. Garrido C, de Mendoza C, Zahonero N, et al. HIV-integrase variability in non-B subtypes and positions potentially associated with resistance to integrase inhibitors. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. 17-20 September 2007, Chicago, IL, USA. Abstract H-1024.
56. Ceccherini-Silberstein F, van Baelen K, Armenia D, et al. Novel HIV-1 integrase mutations, found as minority quasispecies in patients naive to integrase inhibitors, are associated with decreased susceptibility to integrase inhibitors in vitro. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 876.
57. Cocohoba J, Dong BJ. New drug raltegravir: the first HIV integrase inhibitor. Clin Ther 2008; 30:1747-1765.
58. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355-365.
59. Canducci F, Sampaolo M, Marinozzi MC, et al. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS 2009; 23:455-460.
60. Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008; 82:764-774.
61. Serrao E, Odde S, Ramkumar K, Neamati N. Raltegravir, elvitegravir, and metoogravir: the birth of 'me-too' HIV-1 integrase inhibitors. Retrovirology 2009; 6:25.
62. Myers RE, Pillay D. Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase. J Virol 2008; 82:9228-9235.
63. Lataillade M, Chiarella J, Kozal MJ. Links natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 2007; 12:563-570.
64. Yoshinaga T, Nakahara K, Kobayashi M, et al. Resistance profle of the integrase inhibitor S/GSK-364735. 15th Conference on Retroviruses and Opportunistic Infections (CROI). 3-6 February 2008, Boston, MA, USA. Abstract 860.
65. Richman DD (Editor). Human immunodeficiency virus. London: International Medical Press 2003.